Earnings ·
Johnson & Johnson reports Q3 sales of $25.4B, raises full-year adjusted EPS guidance to $11.10
JNJJohnson & Johnson
Johnson & Johnson reported third-quarter 2026 sales of $25.4 billion, a 5.9% increase from the prior year period. Reported diluted earnings per share were $0.09, reflecting a significant one-time special charge related to the proposed resolution of talc litigation and acquisition costs for Firefly Bio and Sail Biomedicines. Adjusted diluted EPS was $2.59. The company raised its full-year 2026 guidance, increasing estimated reported sales to approximately $101.2 billion (7.4% growth) and adjusted diluted EPS by $0.06 to a midpoint of $11.10. Operational sales grew 6.0%, driven by strong performance in the Innovative Medicine segment, particularly oncology products like DARZALEX and CARVYKTI. Johnson & Johnson operates as a diversified healthcare company with segments focused on innovative medicines and medical technology.